TABLE 4

Mutation patterns observed in the BioCAST study

Mutation by biomarker and exonNumber of mutations in the same patientTotal n% of gene% of total
OneTwoThree
BRAF
 Exon 15
  V600E7119
  L597L11
  Total105%
EGFR
 Exon 18
  G719C112
  G719A11
  Unspecified112
  Total53%
 Exon 19
  Deletion74276
  Unspecified1212
  Total8858%
 Exon 20
  c.2303_2305delinsTCT11
  T790M11
  S768I11
  Insertion44
  Duplication11
  Deletion11
  Unspecified11
  Total107%
 Exon 21
  L858R33336
  L861Q415
  Unspecified substitution44
  P848L11
  Unspecified213
  Total4932%
 Unspecified11
  Total11%
 Total15370%
PI3KCA
 Exon 9
  E545K22
  Unspecified substitution11
  Unspecified1180%
 Exon 20
  Unspecified1120%
 Total52%
HER2
 Exon 20
  Unspecified substitution11
  Unspecified insertion55
  Unspecified duplication22
 Total84%
KRAS
 Exon 2
  G13D11
  G12V718
  G12R11
  G12G11
  G12D44
  G12C11
  G12A22
  Unspecified112
 Total209%
ALK
 Unspecified23124
 Total2411%
Total197203220100%
  • BRAF: v-Raf murine sarcoma viral oncogene homologue B; EGFR: epidermal growth factor receptor; PIK3CA: phosphatidylinositol-3-kinase, catalytic subunit α; HER2: human epidermal growth factor receptor 2; KRAS: Kirsten rat sarcoma viral oncogene homologue; ALK: anaplastic lymphoma kinase.